Non-Hodgkin Lymphoma (NHL)

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

July 7th 2025

Marginal zone lymphoma | Image: Atlas of Hematological Cytology

Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

June 24th 2025

Cleveland Clinic Main Campus | Image: Cleveland Clinic

By Laura Joszt, MA

June 19th 2025

large B-cell lymphoma | Image credit: Cleveland Clinic

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

A Look at Those With Durable Responses to Epcoritamab in LBCL

June 17th 2025

Follicular lymphoma | Image: The Follicular Lymphoma Foundation

June 14th 2025

Continuing Medical Education

View All

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Hematologic Cancer, Hematology, Oncology

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

More News

Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com

September 5th 2024

Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma 

Karen Jacobson-Sive

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL).

Dr Jason Romancik, Emory Winship Cancer Institute

August 30th 2024

Dr Jason Romancik on Novel Lymphoma Therapies, Increasing Costs of Care

Rose McNulty

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

Cancerous cells | image credit: Dr_Microbe - stock.adobe.com

August 26th 2024

Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL

Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.

Full results from the inMIND trial of of lenalidomide and rituximab with or without tafasitamab in lymphoma are expected to be submitted for presentation at an upcoming medical meeting. | Image credit: airdone - stock.adobe.com

August 21st 2024

Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point

Jordyn Sava

The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.

Cytokine release concept | image credit: Bijac - stock.adobe.com

August 16th 2024

Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL

CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases.

August 10th 2024

Advancements in R/R Lymphoma: Bispecific Antibodies in Focus

Brooke McCormick Maggie L. Shaw

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

The current lack of comprehensive data reflects an urgent need for more robust data and reporting with regard to BsAbs in R/R non-Hodgkin lymphoma and multiple myeloma. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

August 8th 2024

Scant Infection Data for Patients With R/R MM, NHL Treated With BsAbs

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com

August 1st 2024

Accurately Capturing Experiences of Patients With NHL

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).

July 25th 2024

FDA Approval of Epcoritamab Offers New Hope for R/R Follicular Lymphoma Treatment

Hayden E. Klein

“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.

BeiGene Hopewell facility | Image credit: BeiGene

July 23rd 2024

BeiGene Opens $800M Flagship US Facility in New Jersey

Mary Caffrey

New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.

CAR T | Image Credit: Christoph Burgstedt-stock.adobe.com

July 23rd 2024

In LBCL, Barriers to CAR T Remain: SDOH and More

The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.

July 16th 2024

The Importance of Treatment Sequencing in Mantle Cell Lymphoma

Mary Caffrey Maggie L. Shaw

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com

July 10th 2024

DA-EPOCH-Rituximab: Successfully Treating PMBCL in a Transgender Woman

A case study describes the disparate factors that played into the chemotherapy and other treatment decisions made by a team in Japan when addressing their patient’s primary mediastinal large B-cell lymphoma (PMBCL).

CART and gene therapy | Image Credit: ArtemisDiana-stock.adobe.com

July 9th 2024

Late Effects of CAR T-Cell Therapy in Lymphoma

In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.

non-Hodgkin lymphoma | Image Credit: MQ-Illustrations-stock.adobe.com

July 6th 2024

Study to Quantify Non-Hodgkin Lymphoma Risk in HIV

Karen Jacobson-Sive

This meta-analysis study will estimate the global and regional burden of HIV-associated non-Hodgkin lymphoma to aid the development of prevention and control strategies.

DLBCL | Image Credit: Image Credit: laszlo-stock.adobe.com

July 1st 2024

ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL

The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.

FDA approved | Image credit: ArtEternal – stock.adobe.com

June 27th 2024

Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma

Hayden E. Klein

The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy.

microscopic image of DLBCL | Image Credit: David A Litman-stock.adobe.com

June 17th 2024

Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL

With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.

Medical technology | Image credit: ipopba - stock.adobe.com

June 14th 2024

Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape

Rose McNulty

Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.

June 12th 2024

Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma

Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma.

Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com

June 7th 2024

Obinutuzumab and Radiation Combo Shows Promise for Refractory DLBCL

A small retrospective study found that combining obinutuzumab with radiation therapy may offer a viable and well-tolerated treatment option for patients with refractory diffuse large B-cell lymphoma (DLBCL).

dlbcl | Image Credit: laszlo-stock.adobe.com

June 3rd 2024

How the Tumor Microenvironment Affects DLBCL Prognosis, Treatment

Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments.

Lymphoma word block image | Image Credit: © airdone - stock.adobe.com

May 27th 2024

Key Features of Rare Fibrin-Assisted Diffuse Large B-Cell Lymphoma

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.

Nurse holding older woman's hands | Image Credit: © Cecilie Arcurs/peopleimages.com - stock.adobe.com

May 24th 2024

IVIG Shows Promise in Protecting Older Patients With Lymphoma From COVID-19

Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.

Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com

May 16th 2024

Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL

A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments.

Health costs | Image credit: utah51 - stock.adobe.com

May 8th 2024

Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy

New therapies are helping patients, but are also driving up overall costs of care.

Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com

May 2nd 2024

Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.

IV chemotherapy | Image Credit: Aidman - stock.adobe.com

April 24th 2024

Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL

Luke Halpern

Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com

April 18th 2024

Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes